CN112980770B - Induced Human Pluripotent Stem Cell Directed Endothelial Differentiation Method - Google Patents
Induced Human Pluripotent Stem Cell Directed Endothelial Differentiation Method Download PDFInfo
- Publication number
- CN112980770B CN112980770B CN202110235774.2A CN202110235774A CN112980770B CN 112980770 B CN112980770 B CN 112980770B CN 202110235774 A CN202110235774 A CN 202110235774A CN 112980770 B CN112980770 B CN 112980770B
- Authority
- CN
- China
- Prior art keywords
- differentiation
- cells
- pluripotent stem
- endothelial
- medium containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 11
- 230000009762 endothelial cell differentiation Effects 0.000 title claims abstract description 10
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims abstract description 10
- 230000004069 differentiation Effects 0.000 claims abstract description 31
- 239000002609 medium Substances 0.000 claims abstract description 30
- 210000004027 cell Anatomy 0.000 claims abstract description 22
- 230000001939 inductive effect Effects 0.000 claims abstract description 10
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 8
- 239000001963 growth medium Substances 0.000 claims abstract description 6
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims abstract description 6
- 230000004927 fusion Effects 0.000 claims abstract 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims description 9
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 8
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 8
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 claims description 6
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 claims description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 230000003511 endothelial effect Effects 0.000 abstract description 13
- 230000006698 induction Effects 0.000 abstract description 12
- 108090000695 Cytokines Proteins 0.000 abstract description 2
- 102000004127 Cytokines Human genes 0.000 abstract description 2
- 101150061927 BMP2 gene Proteins 0.000 abstract 2
- 101100502742 Danio rerio fgf8a gene Proteins 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 238000000684 flow cytometry Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 210000003716 mesoderm Anatomy 0.000 description 5
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
技术领域technical field
本发明涉及诱导人类多能干细胞的定向分化领域,具体涉及一种诱导人类多能干细胞定向内皮分化方法。The invention relates to the field of directional differentiation of induced human pluripotent stem cells, in particular to a method for inducing directional endothelial differentiation of human pluripotent stem cells.
背景技术Background technique
心血管疾病(CVD)通常由内皮功能障碍引发,是世界上主要的死亡原因之一。由于缺乏分离足够数量的功能正常的自体内皮细胞(ECs)移植的方法,以及我们对内源性ECs在各种心血管疾病发生过程中如何功能失调的了解有限,直接通过内皮替代治疗CVD受到阻碍。人类诱导多能干细胞(HiPSCs)的创新,即从体细胞重新编程为类似胚胎干细胞(ESC)的多潜能状态的细胞,可以产生大量针对患者的EC,可用于移植、药物筛选或研究,以探索某些疾病状态下内皮功能障碍的机制。然而,目前大多数的内皮分化方案分化效率低下,分化的细胞异质性较大,一定程度上限制了HiPSCs来源的内皮细胞的应用。Cardiovascular disease (CVD), often caused by endothelial dysfunction, is one of the leading causes of death worldwide. Direct endothelial replacement therapy for CVD is hampered by the lack of methods to isolate sufficient numbers of functioning autologous endothelial cells (ECs) for transplantation, and our limited understanding of how endogenous ECs are dysfunctional in the development of various cardiovascular diseases . Innovations in human induced pluripotent stem cells (HiPSCs), cells reprogrammed from somatic cells to a pluripotent state similar to embryonic stem cells (ESCs), can generate large numbers of patient-specific ECs that can be used for transplantation, drug screening or research to explore Mechanisms of endothelial dysfunction in certain disease states. However, most of the current endothelial differentiation protocols have low differentiation efficiency and great heterogeneity of differentiated cells, which limits the application of HiPSCs-derived endothelial cells to a certain extent.
发明内容SUMMARY OF THE INVENTION
本发明所要解决的技术问题是针对上述问题,提供一种诱导人类多能干细胞定向内皮分化方法,本发明解决上述技术问题的技术方案如下:The technical problem to be solved by the present invention is to provide a method for inducing directional endothelial differentiation of human pluripotent stem cells in view of the above-mentioned problems. The technical solution of the present invention to solve the above-mentioned technical problems is as follows:
诱导人类多能干细胞定向内皮分化方法,包括以下步骤:A method for inducing human pluripotent stem cells directed endothelial differentiation, including the following steps:
步骤1、第0-1天:人类诱导多能干细胞达到80%融合以上时,使用含有10-50ng/mlWNT3a和1μmol/L SU5402的RPMI/B27分化培养基,对消化后的人类诱导多能干细胞进行诱导分化;
步骤2、第1-2天:使用含有10-50ng/ml WNT3a、10-30ng/ml BMP2和1μmol/LSU5402的RPMI/B27分化培养基,对步骤1诱导分化后的细胞继续诱导分化;Step 2, Day 1-2: Use RPMI/B27 differentiation medium containing 10-50ng/ml WNT3a, 10-30ng/ml BMP2 and 1μmol/LSU5402 to continue to induce differentiation of cells after induction in
步骤3、第2-3天:使用含有10-30ng/ml BMP2和1μmol/L SU5402的RPMI/B27分化培养基,对步骤2诱导分化后的细胞继续诱导分化为中胚层细胞;Step 3. Days 2-3: Use RPMI/B27 differentiation medium containing 10-30ng/ml BMP2 and 1μmol/L SU5402, and continue to induce differentiation into mesoderm cells after induction and differentiation in Step 2;
步骤4、第4-9天:使用含有30-50ng/ml VEGF、10-15ng/ml FGF8和10-15ng/mlbFGF的EGM-2/B27培养基,对步骤3诱导分化后的细胞继续诱导分化为内皮细胞。Step 4. Days 4-9: Use EGM-2/B27 medium containing 30-50ng/ml VEGF, 10-15ng/ml FGF8 and 10-15ng/ml bFGF, continue to induce differentiation of cells after induction in step 3 for endothelial cells.
进一步的,所述步骤2和步骤3中分化培养基中WNT3a的浓度为10ng/ml,BMP2的浓度为10ng/ml。Further, in the steps 2 and 3, the concentration of WNT3a in the differentiation medium is 10 ng/ml, and the concentration of BMP2 is 10 ng/ml.
进一步的,所述步骤4的培养基中FGF8的浓度为10ng/ml。Further, the concentration of FGF8 in the medium of step 4 is 10ng/ml.
本发明的有益效果为:通过改良培养基及相关细胞因子,本实验方案可以具备更高的内皮诱导效率。The beneficial effects of the present invention are: by improving the culture medium and related cytokines, the experimental scheme can have higher endothelial induction efficiency.
附图说明Description of drawings
图1为中胚层标志物CD15的流式细胞图;Figure 1 is a flow cytometry diagram of mesoderm marker CD15;
图2为内皮标志物CD31、CD144双标流式细胞图;Figure 2 is a flow cytometry chart of double-labeled endothelial markers CD31 and CD144;
图3为内皮标志物单标CD144流式细胞图;Figure 3 is a flow cytometry diagram of endothelial marker CD144;
图4为内皮标志物单标CD31流式细胞图。Figure 4 is a flow cytometry diagram of the endothelial marker single-labeled CD31.
具体实施方式Detailed ways
以下结合附图对本发明的原理和特征进行描述,所举实例只用于解释本发明,并非用于限定本发明的范围。The principles and features of the present invention will be described below with reference to the accompanying drawings. The examples are only used to explain the present invention, but not to limit the scope of the present invention.
诱导人类多能干细胞定向内皮分化方法,包括以下步骤:A method for inducing human pluripotent stem cells directed endothelial differentiation, including the following steps:
HiPSCs的维持Maintenance of HiPSCs
HiPSCs常规培养在含有mTeSR1培养基的Matrigel上。每隔3-5天用Versen3-5传代一次,在35mm培养板上细胞需要80%融合才能开始分化。HiPSCs were routinely grown on Matrigel containing mTeSR1 medium. Passage with Versen3-5 every 3-5 days, cells need to be 80% confluent on 35mm culture plates to start differentiation.
第0天:Day 0:
铺胶:Matrigel在冰上解冻,以无生长因子的DMEM培养基1:100稀释后,平铺在60mm的培养板上,37℃孵育0.5h。吸除培养基,用DPBS(不含Ca2+和Mg2+)清洗一次,加入4.5ml预热的mTeSR1+ROCK抑制剂Y27632(终浓度10μM)。Spreading: Matrigel was thawed on ice, diluted 1:100 with growth factor-free DMEM medium, spread on a 60mm culture plate, and incubated at 37°C for 0.5h. The medium was aspirated, washed once with DPBS (without Ca2+ and Mg2+), and 4.5 ml of pre-warmed mTeSR1+ROCK inhibitor Y27632 (
消化种板:将mTeSR1生长培养基从80%汇合的35mm细胞培养板中吸除,用2ml预热的DPBS清洗。加入2毫升预热的TriplE,37℃孵育5-10分钟,显微镜下检查细胞脱落情况。在上述加入1-2ml预热的mTeSR1,将细胞转移到15毫升的离心管中。在1000rpm(210g)下离心5min后,吸除上清液2ml预热的mTeSR1培养基重新悬浮细胞后进行细胞计数。以每平方厘米20000-30000个细胞接种于在铺胶的培养皿上。在37℃、5%二氧化碳中孵育细胞过夜。Digest seed plate: Aspirate mTeSR1 growth medium from 80% confluent 35 mm cell culture plate and wash with 2 ml of pre-warmed DPBS. Add 2 ml of pre-warmed TriplE, incubate at 37°C for 5-10 minutes, and check for cell detachment under a microscope. Add 1-2 ml of pre-warmed mTeSR1 above and transfer the cells to a 15-ml centrifuge tube. After centrifugation at 1000 rpm (210 g) for 5 min, the supernatant was removed by aspirating 2 ml of pre-warmed mTeSR1 medium and the cells were resuspended for cell counting. 20,000-30,000 cells per square centimeter were plated on gel-coated dishes. Cells were incubated overnight at 37°C, 5% carbon dioxide.
中胚层诱导阶段(第1-3天):Mesoderm induction stage (days 1-3):
中胚层诱导第1天:用预热的RPMI/B27培养基+10ng/ml WNT3a+1μmol/L SU5402(4.5ml/60mm平板/2ml/6孔)更换原培养基。第2天:用预热的含10ng/ml WNT3a+10ng/mlBMP2+1μmol/L SU5402的RPMI/B27培养基(4.5ml/60mm平板/2ml/6孔)更换原培养基。第3天:用含10ng/ml BMP2+1μmol/L SU5402(4.5ml/60mm培养皿/2ml/6孔)的预热RPMI/B27培养基更换原培养基。Mesoderm induction day 1: Replace the original medium with pre-warmed RPMI/B27 medium + 10 ng/ml WNT3a + 1 μmol/L SU5402 (4.5 ml/60 mm plate/2 ml/6 wells). Day 2: Replace the original medium with pre-warmed RPMI/B27 medium (4.5ml/60mm plate/2ml/6 wells) containing 10ng/ml WNT3a+10ng/ml BMP2+1μmol/L SU5402. Day 3: Replace the original medium with pre-warmed RPMI/B27 medium containing 10ng/ml BMP2+1μmol/L SU5402 (4.5ml/60mm dish/2ml/6 well).
内皮诱导阶段(第4-9天):Endothelial induction phase (days 4-9):
第4天Day 4
铺胶:Matrigel在冰上解冻,以无生长因子的DMEM培养基1:100稀释后,平铺在60mm的培养皿上,37℃孵育0.5h。吸除培养基,用DPBS(不含Ca2+和Mg2+)清洗一次,加入4.5ml预热的EGM-2/B27诱导分化培养基+ROCK抑制剂Y27632(终浓度10μM),并加入30ng/mlVEGF+10ng/ml FGF8+10ng/ml bFGF。Laying: Matrigel was thawed on ice, diluted 1:100 with growth factor-free DMEM medium, spread on a 60mm petri dish, and incubated at 37°C for 0.5h. Aspirate the medium, wash once with DPBS (without Ca2+ and Mg2+), add 4.5ml of pre-warmed EGM-2/B27 induction differentiation medium + ROCK inhibitor Y27632 (final concentration 10μM), and add 30ng/ml VEGF+10ng /ml FGF8 + 10ng/ml bFGF.
消化种板:将生长培养基从80%汇合的60mm培养皿中吸除。用2ml预热的DPBS(不含Ca2+和Mg2+)清洗。加入2毫升预热的TriplE,37℃孵育5-10分钟,显微镜下检查细胞脱落情况。加入1-2ml预热的EGM-2培养基。将细胞转移到15毫升的离心管中。在1000rpm(210g)下离心5min后进行细胞计数,以每平方厘米5000个细胞的密度接种在预铺胶的培养皿上。在37℃、5%二氧化碳中孵育细胞过夜。用添加30ng/ml VEGF+10ng/ml FGF8+10ng/ml bFGF的EGM-2/B27培养基(4.5ml/60mm平板/2ml/6孔)更换培养基,每隔一天换一次培养基。Digest seed plate: Aspirate growth medium from 80% confluent 60 mm dishes. Wash with 2 ml of pre-warmed DPBS (without Ca2+ and Mg2+). Add 2 ml of pre-warmed TriplE, incubate at 37°C for 5-10 minutes, and check for cell detachment under a microscope. Add 1-2 ml of pre-warmed EGM-2 medium. Transfer the cells to a 15 mL centrifuge tube. Cells were counted after centrifugation at 1000 rpm (210 g) for 5 min and seeded on pre-gelatinized dishes at a density of 5000 cells per square centimeter. Cells were incubated overnight at 37°C, 5% carbon dioxide. The medium was replaced with EGM-2/B27 medium (4.5ml/60mm plate/2ml/6 wells) supplemented with 30ng/ml VEGF+10ng/ml FGF8+10ng/ml bFGF every other day.
如图1所示为中胚层标志物CD15的流式细胞图;由图1可看出HiPSCs分化为中胚层CD15的分化效率为99.1%(图1的P2区域);Figure 1 shows the flow cytometry of the mesoderm marker CD15; it can be seen from Figure 1 that the differentiation efficiency of HiPSCs into mesoderm CD15 is 99.1% (P2 area in Figure 1);
如图2所示为内皮标志物CD31、CD144双标流式细胞图;由图2可看出在该分化方案诱导下,HiPSCs分化为内皮标志物CD31、CD144双标的分化效率为63.8%(图2的Q2区域);Figure 2 shows the flow cytometry diagram of the endothelial markers CD31 and CD144 double-labeling; it can be seen from Figure 2 that under the induction of the differentiation protocol, the differentiation efficiency of HiPSCs into the endothelial markers CD31 and CD144 double-labeling was 63.8% (Fig. 2's Q2 area);
如图3所示为内皮标志物单标CD144流式细胞图;由图3可看出在该分化方案诱导下,HiPSCs分化为内皮标志物CD144的分化效率为86.2%(图3的P2区域);Figure 3 shows the flow cytometry chart of endothelial marker CD144; it can be seen from Figure 3 that under the induction of this differentiation protocol, the differentiation efficiency of HiPSCs into endothelial marker CD144 is 86.2% (P2 area in Figure 3) ;
如图4所示为内皮标志物单标CD31流式细胞图;由图4可看出在该分化方案诱导下,HiPSCs分化为内皮标志物CD31的分化效率为56.3%(图4的P3区域)。Figure 4 shows the flow cytometry diagram of the endothelial marker CD31; it can be seen from Figure 4 that the differentiation efficiency of HiPSCs into endothelial marker CD31 under the induction of this differentiation protocol is 56.3% (P3 area in Figure 4) .
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection of the present invention. within the range.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110235774.2A CN112980770B (en) | 2021-03-03 | 2021-03-03 | Induced Human Pluripotent Stem Cell Directed Endothelial Differentiation Method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110235774.2A CN112980770B (en) | 2021-03-03 | 2021-03-03 | Induced Human Pluripotent Stem Cell Directed Endothelial Differentiation Method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112980770A CN112980770A (en) | 2021-06-18 |
CN112980770B true CN112980770B (en) | 2022-08-02 |
Family
ID=76352414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110235774.2A Active CN112980770B (en) | 2021-03-03 | 2021-03-03 | Induced Human Pluripotent Stem Cell Directed Endothelial Differentiation Method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112980770B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2100954A1 (en) * | 2008-03-10 | 2009-09-16 | Assistance Publique - Hopitaux de Paris | Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications |
CN101641436A (en) * | 2007-01-30 | 2010-02-03 | 佐治亚大学研究基金会 | Be used to produce the promptly stable mesendoderm cell mass of early stage mesoblastema of entoderm and mesoblastema system and multipotency wandering cell (MMC) |
CN109797132A (en) * | 2019-03-15 | 2019-05-24 | 苏州大学 | A method of promotion human pluripotent stem cells directed differentiation is endothelial cell |
CN110438065A (en) * | 2019-07-25 | 2019-11-12 | 中山大学 | A method of induction people's inductive pluripotent stem cells are divided into endothelial progenitor cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2951290B1 (en) * | 2013-02-01 | 2017-11-29 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Method for generating retinal pigment epithelium (rpe) cells from induced pluripotent stem cells (ipscs) |
-
2021
- 2021-03-03 CN CN202110235774.2A patent/CN112980770B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101641436A (en) * | 2007-01-30 | 2010-02-03 | 佐治亚大学研究基金会 | Be used to produce the promptly stable mesendoderm cell mass of early stage mesoblastema of entoderm and mesoblastema system and multipotency wandering cell (MMC) |
EP2100954A1 (en) * | 2008-03-10 | 2009-09-16 | Assistance Publique - Hopitaux de Paris | Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications |
CN109797132A (en) * | 2019-03-15 | 2019-05-24 | 苏州大学 | A method of promotion human pluripotent stem cells directed differentiation is endothelial cell |
CN110438065A (en) * | 2019-07-25 | 2019-11-12 | 中山大学 | A method of induction people's inductive pluripotent stem cells are divided into endothelial progenitor cells |
Non-Patent Citations (2)
Title |
---|
Efficient Differentiation of Human Pluripotent Stem Cells to Endothelial Cells;Mingxia Gu;《Curr Protoc Hum Genet. Author manuscript》;20200106;第1-21页 * |
诱导性多能干细胞与心血管疾病;詹琪 等人;《中国组织工程研究》;20160902;第5440-5449页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112980770A (en) | 2021-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mamidi et al. | Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation | |
CN108359636B (en) | Induction method for improving directed differentiation of pluripotent stem cells into myocardial cells | |
CN109797132B (en) | Method for promoting directional differentiation of human pluripotent stem cells into endothelial cells | |
US11052120B2 (en) | Method of committed differentiation of human induced pluripotent stem cells into Leydig cells and application of Leydig cells | |
CN101341245A (en) | Methods for Obtaining Progenitor Cell Lines | |
Wu et al. | Derivation of multipotent nestin+/CD271−/STRO-1− mesenchymal-like precursors from human embryonic stem cells in chemically defined conditions | |
CN105779395A (en) | Immortalized canine adipic mesenchymal stem cell line and constructing method thereof | |
CN102533659A (en) | Method for inducing human umbilical cord mesenchymal stem cells into testicular interstitial cells and application thereof | |
CN105331583B (en) | A method of promote people to induce multi-potent stem cell and breaks up to Neuronal induction | |
WO2019228518A1 (en) | Differentiation medium and method for preparing oligodendrocyte precursor | |
CN106520687A (en) | Method for differentiating induced pluripotent stem cells into mesenchymal stem cells | |
CN107475188A (en) | A kind of cultural method of cell culture medium and embryonic stem cell | |
CN105331579A (en) | Separation and culture method and application of human testis mesenchymal stem cells | |
CN104946590A (en) | Method for inducing Muse cells in adult bone marrow into neural precursor cells (NPCs) | |
CN112980770B (en) | Induced Human Pluripotent Stem Cell Directed Endothelial Differentiation Method | |
CN105238758A (en) | In-vitro hematopoietic stem cell/ progenitor cell acquisition method | |
CN102021143B (en) | Pretreatment method for improving migration capability of mesenchymal stem cells | |
Song et al. | bFGF promotes adipocyte differentiation in human mesenchymal stem cells derived from embryonic stem cells | |
US20180105796A1 (en) | Method of Inducing and Differentiating Human Skin-Derived Precursors to Differentiate into Corneal Endothelial-like Cells | |
CN108795842B (en) | A method and application of 3D suspension inducing iPS cells to generate autologous melanocytes | |
CN104862279A (en) | Method of non-exogenous induction of pluripotent stem cell to be GABA (Gamma Amino Acid Butyric Acid) neuron and application | |
CN115232788B (en) | Mesenchymal stem cells derived from definitive endoderm cells and differentiation method and application thereof | |
KR101984227B1 (en) | The method for isolation of stem cells from bone marrow using subfractionation culturing method and proliferation thereof | |
CN109943531A (en) | Primary culture method of glioblastoma stem cells | |
CN103881962A (en) | Method of establishing rat pancreatic duct epithelioid stem cell system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |